COMPARISON OF EFFICACY OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPEUTICS MITOMYCIN C VERSUS OXALIPLATIN IN EXPERIMENTAL COLORECTAL PERITONEAL METASTASIS MODEL.
| Autor: | Manoglu, Berke, Canda, Aras Emre, Yavuzsen, Tugba, Aktas, Safiye, Altun, Zekiye, Yılmaz, Osman, Bisgin, Tayfun |
|---|---|
| Předmět: |
VASCULAR endothelial growth factors
T-test (Statistics) RESEARCH funding THERMOTHERAPY ABDOMINAL surgery ENZYME-linked immunosorbent assay APOPTOSIS KRUSKAL-Wallis Test FISHER exact test CELL physiology MITOMYCINS COLORECTAL cancer DESCRIPTIVE statistics CHI-squared test TRANSCRIPTION factors ADJUVANT chemotherapy METASTASIS MICE OXALIPLATIN DRUG efficacy ANIMAL experimentation PERITONEUM tumors COMPARATIVE studies MICROSCOPY DATA analysis software TUMOR necrosis factors |
| Zdroj: | Journal of Basic & Clinical Health Sciences; Jan2024, Vol. 8 Issue 1, p181-191, 11p |
| Abstrakt: | Aim: Our study aimed to establish a mouse model with colorectal cancer-induced peritoneal metastasis(PM) and to compare the efficacy of hyperthermic intraperitoneal chemotherapeutic agents, mitomycin C and oxaliplatin. Materials and Methods: The peritoneal metastasis model was established in nude mice using the CC531 colon carcinoma cell line. Models with PM were randomized into four groups of seven animals each: Group-1, control group; Group-2, hyperthermic intraperitoneal chemotherapy(HIPEC) with mitomycin C(MMC), and Group-3, HIPEC with Oxaliplatin(OXA). Results: Tumor development was achieved in all animals. While the tumor burden decreased significantly in the treatment Group-2(p=.013). In the PM mouse model, hyperthermic intraperitoneal administration of MMC had a higher tumoricidal effect than hyperthermic intraperitoneal administration of OXA. Conclusions: Our PM model provided a good opportunity to examine the efficacy of HIPEC and IPIP. Hyperethermic intraperitoneal mitomycin applied in the colorectal PM animal model was found to have higher tumoricidal activity than oxaliplatin. In future studies, we plan to evaluate efficacies of different drugs in the PM models we have created. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|